Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults
Dateline City:
BOSTON
Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today presented data from the dose-ranging portion of an ongoing Phase
2B clinical trial of doravirine, the company’s investigational
next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI),
at the 21st Conference on Retroviruses and Opportunistic
Infections (CROI).
Language:
English
Contact:
MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news